Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

OXiGENE regains compliance for continued listing on NASDAQ Global Market

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)

7 Apr 2010

Why is the genome project not yielding results faster?

As the genome projects reaches the 10 year landmark scientists are defending it. While the sequencing of the 3 billion letters in the human DNA took a long time the first draft of the human genome was presented ten years ago. Today it is possible to have your individual DNA mapped in a day and at the low cost of $5,000.

5 Apr 2010

BeaconEquity.com announces investment report featuring OXiGENE

BeaconEquity.com announces an investment report featuring OXiGENE Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

1 Apr 2010

Scientists use non-viral, synthetic nanoparticle carrier to restores vision

Take a look at this: Scientists from Buffalo, Cleveland, and Oklahoma City made a huge step toward making the blind see, and they did it by using a form of gene therapy that does not involve the use of modified viruses.

1 Apr 2010

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

A Kansas State University researcher is exploring the use of Chinese wolfberries to improve vision deficiencies that are common for type-2 diabetics.

31 Mar 2010

READ 3 study for DME begins enrolling participants

A Phase II clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.

27 Mar 2010

New topical drug may help treat diabetic eye disease

Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.

26 Mar 2010

OXiGENE reports audited financial statements for fiscal year ended December 31, 2009

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that the audit report from its independent registered public accounting firm on its financial statements for the fiscal year ended December 31, 2009, included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 16, 2010, contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

19 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

OVD issue highlights prevalence of eye problems in general population

In the latest issue of Optometry & Vision Development (OVD), Dr. Dominick Maino, editor of OVD, notes that: "In 2010 there are 9 million people with lazy eye and 18 million individuals with eye-turns

17 Mar 2010

OXiGENE signs definitive agreement to sell Common Stock

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.

12 Mar 2010

$TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers$

TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers

OccuLogix, Inc., dba TearLab Corporation, announced today that TLCVision Corporation, North America's premier eye care services company, will be incorporating the TearLab™ Osmolarity System in eight of its U.S. refractive surgery centers to study Dry Eye Disease symptoms as they relate to LASIK surgery.

11 Mar 2010

World through the eyes of a person with eye disease

Lighthouse International, the non-profit leader in vision healthcare, research, education and advocacy, launches a new website that features the first customizable, low-vision simulator that shows how a person with an eye disease sees the world. Visitors can choose a video from YouTube and select a filter that simulates retinitis pigmentosa, macular degeneration, glaucoma or diabetic retinopathy.

6 Mar 2010

Crowding essentially 'blends' nearby objects together and makes the world appear more regular

As you read this, you may notice that the word directly in front of you is clear, but all the surrounding words are hard to make out. For most people, this effect - known as 'crowding' - is not a problem. However, for the millions of people worldwide who have lost their central vision through eye disease such as macular degeneration, it can make everyday tasks such as reading or recognising friends a challenge.

5 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s MA09-hRPE cells for use in the treatment of Stargardt’s Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.

3 Mar 2010

Visually impaired children benefit from earlier introduction to long cane

When "T" started kindergarten, she was an independent, confident child who was fully able to move about in her new environment—even though she was the only visually impaired child in her school and used a long cane. T was born in 2003 with Leber's congenital amaurosis, a rare inherited eye disease, and has no light perception. She was introduced to the long cane at the early age of 14 months to foster her independence of mobility and functioning.

2 Mar 2010

University of Michigan Health System opens new facility for eye care, diabetes research

On March 1, the first eye patients will enter an innovative new $132 million facility that expands the University of Michigan Health System's capacity for eye care, research and education, and unites diabetes researchers as they work to accelerate the search for a cure and prevention of diabetes.

27 Feb 2010

Report: Green tea catechins may protect against glaucoma and other common eye diseases

Scientists have confirmed that the healthful substances found in green tea - renowned for their powerful antioxidant and disease-fighting properties - do penetrate into tissues of the eye. Their new report, the first documenting how the lens, retina, and other eye tissues absorb these substances, raises the possibility that green tea may protect against glaucoma and other common eye diseases.

19 Feb 2010

UWM engineer creates software program that foresees outcome before stem cell divides

A software program created by an engineer at the University of Wisconsin-Milwaukee (UWM) can not only predict the types of specialized cells a stem cell will produce, but also foresee the outcome before the stem cell even divides.

17 Feb 2010